Helsinn, Dr Reddy's settle patent dispute
14 October 2015 | News | By BioSpectrum Bureau
Helsinn, Dr Reddy's settle patent dispute
Dr Reddy's will be permitted to market a generic version of Aloxi in the United States
Helsinn Healthcare SA announces that it has entered into a settlement agreement with Dr Reddy's Laboratories to resolve certain patent litigations relating to Helsinn Healthcare's Aloxi (palonosetron HCl injection) in the United States, where it is currently distributed by Helsinn Healthcare's marketing partner, Eisai.
As a result of the settlement, Dr Reddy's will be permitted to market a 505(j) generic version of Aloxi in the United States on September 30, 2018 or earlier under certain circumstances. The terms of the settlement agreement are otherwise confidential.
